Completion of Placing-Replace

Seeing Machines Limited 31 October 2007 31 October 2007 This announcement replaces RNS number 6622G, the Completion of Placing, Issue of Shares, Directors' Interests and Change in Shareholdings announcement from Seeing Machines released at 07:01am this morning. The change relates to the shareholding of David Gaul. The line which stated that, as of 31 October 2007, David Gaul's shareholding would be 1,834,000 should have instead stated that this shareholding would be 1,834,800. Seeing Machines Limited ('Seeing Machines' or the 'Company') Completion of Placing, Issue of Shares, Directors' Interests and Change in Shareholdings Seeing Machines (AIM: SEE), a leading developer of advanced computer based imaging software systems, has completed the combined placings, the subject of the announcements made on 24 and 25 September and 26 October, issuing a further 47,652,000 ordinary shares at 2.5p per share bringing the total number of new ordinary shares issued in the placings to 56,000,000 ordinary shares. The Company has raised £1.4 million before expenses in the placings. The further 47,652,000 new ordinary shares have been admitted for trading on AIM today. This brings the total share capital of the company to 312,164,929. Following the issue of these 47,652,000 new ordinary shares the Company is aware of the following relevant changes in directors' and connected persons' shareholdings and substantial and significant shareholdings as defined in the AIM Rules for Companies. Directors and Connected Persons Shareholdings +------------+----+--------------------------+--------------------------+ | |Note| To 30 October 2007| As of 31 October 2007| +------------+----+-----------+--------------+-----------+--------------+ |Shareholder | |Shares Held|% shareholding|Shares Held|% shareholding| +------------+----+-----------+--------------+-----------+--------------+ |Alexander | 1| 85,594,176| 32.36%| 85,644,264| 27.44%| |Zelinsky1 | | | | | | +------------+----+-----------+--------------+-----------+--------------+ |Trent | | | | 50,088| 0.02%| |William | | | | | | |Victor | | | | | | +------------+----+-----------+--------------+-----------+--------------+ |Rob Sale2 | 2| 5,115,512| 0.84%| 5,115,512| 0.71%| +------------+----+-----------+--------------+-----------+--------------+ |Nick Cerneaz| | 391,914| 0.15%| 1,467,332| 0.47%| +------------+----+-----------+--------------+-----------+--------------+ |William | 3| | | 400,704| 0.13%| |Mobbs3 | | | | | | +------------+----+-----------+--------------+-----------+--------------+ |David Gaul4 | 4| 1,000,000| 0.38%| 1,834,800| 0.59%| +------------+----+-----------+--------------+-----------+--------------+ 1. Alexander Zelinsky, a director of Seeing Machines, holds 25% of the issued shares in JATS Technology Pty Ltd which has 85,594,176 ordinary shares in Seeing Machines. Mr. Zelinsky holds 50,088 Seeing Machines shares in his own name. 2. Rob Sale's shares are 2,209,143 shares held in the name of Caffe Pty Ltd ATF the R C Sale Superannuation Fund and 2,906,369 shares held by Rob's wife Paula Kay Sale. 3. William Mobbs shares are held in the names of William Mobbs and Catherine Holbery ATF The Bilbo Super Fund 4. David Gaul holds 1,834,800 shares through his company Jaiclimb Pty Limited. Significant and Substantial Shareholdings +-----------------+---------------------------+---------------------------+ | | To 30 October 2007| As of 31 October 2007| +-----------------+------------+--------------+-----------+---------------+ |Shareholder | Shares Held|% shareholding|Shares Held| % shareholding| +-----------------+------------+--------------+-----------+---------------+ |JATS Technology | 85,594,176| 32.36%| 85,594,176| 27.42%| |Pty Limited1 | | | | | +-----------------+------------+--------------+-----------+---------------+ |Australian | 36,462,867| 13.78%| 36,462,867| 11.68%| |National | | | | | |University | | | | | +-----------------+------------+--------------+-----------+---------------+ |Volvo | 23,226,073| 8.78%| 23,226,073| 7.44%| |Technological | | | | | |Development | | | | | +-----------------+------------+--------------+-----------+---------------+ |Volvo Technology | | | 16,000,000| 5.13%| |Transfer AB | | | | | +-----------------+------------+--------------+-----------+---------------+ |Pershing Keen | 10,916,642| 4.13%| 10,916,642| 3.50%| |Nominees Limited | | | | | +-----------------+------------+--------------+-----------+---------------+ |HSBC Global | | | 10,000,000| 3.20%| |Custody Nominee | | | | | |(UK) Limited | | | | | +-----------------+------------+--------------+-----------+---------------+ |Pershing Keen | 9,264,999| 4%| 9,264,999| 2.97%| |Nominees Limited | | | | | +-----------------+------------+--------------+-----------+---------------+ |Roy Nominees | 9,165,000| 3.46%| 9,165,000| 2.94%| |Limited | | | | | +-----------------+------------+--------------+-----------+---------------+ --- ENDS --- Enquiries: Seeing Machines Limited Insinger de Beaufort Parkgreen Communications Nick Cerneaz, CEO Peter Ward, Chris Justine Howarth, Erica Caldwell Nelson +61 (0) 2 6125 6501 +44 (0) 20 7190 7015 +44 (0) 20 7851 7480 www.seeingmachines.com Notes to editors: About Seeing Machines Seeing Machines is an award winning Technology Company which focuses on vision based human machine interfaces. Formed in 2000 in Canberra, Australia, Seeing Machines' purpose is to commercialise its computer-vision across a range of industries and applications. Seeing Machines deliver advanced computer vision solutions for researches and developers in human factors, transportation safety, computer human interaction, robotics, medical research and psychology. The flagship product faceLAB(R) provides an automated and contact-free gaze and head tracking technology, it solves the problem of observing human behaviour naturally, non-intrusively and with a high degree of accuracy and usability. Building on these unique face tracking and pupil measurement and monitoring capabilities, the TrueField Analyzer(R) is new medical device to assist clinicians detect and manage eye diseases such as glaucoma. The TrueField Analyzer(R) offers a new objective method to help doctors diagnose and manage a range of eye diseases including glaucoma, age related macular degeneration and diabetic retinopathy. Glaucoma affects about 2-3% of the population over 40 years of age and is a leading source of blindness. Unlike most other devices available to the clinician the TrueField Analyzer is a completely objective test and it is quick and easy for patients and technicians alike. The device measures both eyes concurrently and due to the reliability that arises from the objective nature of the test, it has the potential to become a new standard in the measurement of visual field defects and thus in the diagnosis and management of disease such as glaucoma. More generally Seeing Machines' computer vision systems are able to measure the orientation and position of a human head, estimate eye-gaze direction, detect eye blinks and track other facial features. This functionality is achieved entirely though visual means, using video cameras connected to advanced image processing software, with no attachments required on the subject. Products such as faceLAB(R) are designed to allow human factors researchers and designers to assess the interaction of an operator in an environment and this finds application in designing operator environments, such as cockpits for cars, trucks, trains, and aeroplanes for instance, and other industrial design applications, as well as medical and psychological research situations. The technology has been developed into the Driver State Sensor (DSS2) product for application in monitoring vehicle drivers and if it detects drowsiness (fatigue) or that the driver is distracted and their attention has been diverted from the road, alarms are raised to alert the driver to these events. In larger deployments, such as in fleet and mining equipment operations, the data is available in both real-time and off-line modes for fleet management, driver training and awareness programs The systems work in real-time, enabling the behaviour of subjects to be tracked in real-time. This technology is paving the way in promoting safer driving conditions and works to enhance the driving experience and to eliminate accidents caused through driver drowsiness or distraction. There are many different sectors that can benefit from this revolutionary software, for which it has been developed, including: automotive; academic research; medicine/healthcare; defence; autostereoscopy (next generation displays); sport; and games. This information is provided by RNS The company news service from the London Stock Exchange
UK 100

Latest directors dealings